CP 55,940: Difference between revisions
CSV import |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
== CP 55,940 == | |||
[[File:CP_55,940-2D-skeletal.svg|thumb|right|200px|2D skeletal structure of CP 55,940]] | |||
'''CP 55,940''' is a synthetic [[cannabinoid]] that was developed in the 1970s by the pharmaceutical company [[Pfizer]]. It is a potent agonist of the [[cannabinoid receptor]]s, specifically the [[CB1 receptor]] and [[CB2 receptor]]. CP 55,940 is often used in scientific research to study the [[endocannabinoid system]] and its effects on the body. | |||
CP 55,940 | |||
== | == Chemical Structure and Properties == | ||
== | CP 55,940 is a [[bicyclic]] compound with a complex structure that includes a [[cyclohexane]] ring and a [[phenol]] group. The chemical formula of CP 55,940 is C23H32O2, and it has a molecular weight of 340.5 g/mol. The compound is lipophilic, allowing it to easily cross the [[blood-brain barrier]] and interact with cannabinoid receptors in the [[central nervous system]]. | ||
== Mechanism of Action == | |||
CP 55,940 acts as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the [[G protein-coupled receptor]] family and are primarily involved in modulating [[neurotransmitter]] release in the brain. Activation of CB1 receptors by CP 55,940 leads to a decrease in [[neurotransmitter]] release, which can result in effects such as [[analgesia]], [[sedation]], and [[appetite stimulation]]. | |||
== Research Applications == | |||
CP 55,940 is widely used in research to explore the physiological and pharmacological roles of the endocannabinoid system. It is often employed in studies investigating the effects of cannabinoids on [[pain]], [[inflammation]], and [[neurodegenerative diseases]]. Additionally, CP 55,940 is used to study the potential therapeutic applications of cannabinoids in conditions such as [[multiple sclerosis]], [[epilepsy]], and [[cancer]]. | |||
== Safety and Toxicity == | |||
As a research chemical, CP 55,940 is not intended for human consumption. Studies have shown that it can produce effects similar to those of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]]. However, due to its potency, CP 55,940 can also lead to more pronounced side effects, including [[anxiety]], [[paranoia]], and [[tachycardia]]. | |||
== Related Pages == | |||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[Endocannabinoid system]] | |||
* [[Synthetic cannabinoids]] | |||
* [[Tetrahydrocannabinol]] | * [[Tetrahydrocannabinol]] | ||
[[Category: | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Pharmacology]] | ||
Latest revision as of 19:59, 15 February 2025
CP 55,940[edit]
CP 55,940 is a synthetic cannabinoid that was developed in the 1970s by the pharmaceutical company Pfizer. It is a potent agonist of the cannabinoid receptors, specifically the CB1 receptor and CB2 receptor. CP 55,940 is often used in scientific research to study the endocannabinoid system and its effects on the body.
Chemical Structure and Properties[edit]
CP 55,940 is a bicyclic compound with a complex structure that includes a cyclohexane ring and a phenol group. The chemical formula of CP 55,940 is C23H32O2, and it has a molecular weight of 340.5 g/mol. The compound is lipophilic, allowing it to easily cross the blood-brain barrier and interact with cannabinoid receptors in the central nervous system.
Mechanism of Action[edit]
CP 55,940 acts as a full agonist at both the CB1 and CB2 receptors. These receptors are part of the G protein-coupled receptor family and are primarily involved in modulating neurotransmitter release in the brain. Activation of CB1 receptors by CP 55,940 leads to a decrease in neurotransmitter release, which can result in effects such as analgesia, sedation, and appetite stimulation.
Research Applications[edit]
CP 55,940 is widely used in research to explore the physiological and pharmacological roles of the endocannabinoid system. It is often employed in studies investigating the effects of cannabinoids on pain, inflammation, and neurodegenerative diseases. Additionally, CP 55,940 is used to study the potential therapeutic applications of cannabinoids in conditions such as multiple sclerosis, epilepsy, and cancer.
Safety and Toxicity[edit]
As a research chemical, CP 55,940 is not intended for human consumption. Studies have shown that it can produce effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. However, due to its potency, CP 55,940 can also lead to more pronounced side effects, including anxiety, paranoia, and tachycardia.
